Guibao Ke, Peian Chen, Jing Luo, Junlin Huang, Yuqi Shang, Yongzhang Huang, Ningying Fu, Hongbo Peng, Yuan Li, Bo Wang, Weijie Guan, Yonghua Peng, Xiaomin Yu, Jie Xiao
Immune checkpoint inhibitors (ICIs), including antiprogrammed cell-death (PD)-1/anti-PD-ligand (PDL-1) monoclonal antibodies, are effective at improving the prognosis of patients with cancer. Among immune-related adverse events, myocarditis associated with anti-PD-1/anti-PD-L1 antibodies is rare but lacks effective treatment and mortality is very high. In this study, the authors extracted data from the previous 8 years from electronic medical records housed in the hospital information system to identify patients hospitalized with myocarditis putatively caused by anti-PD-1/anti-PD-L1 tumor therapy...
September 12, 2023: Clinical Cardiology